Eisai, MGI Pharma merger clears waiting period hurdle

By Lisa Kerner

Charlotte, N.C., Jan. 17 - The Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting period in the proposed merger of Eisai Co., Ltd. and MGI Pharma, Inc.

Jaguar Acquisition, Corp., an Eisai subsidiary, began an all-cash offer on Dec. 21 to purchase all outstanding shares MGI Pharma.

The $41-per-share offer is slated to end on Jan. 22, according to a company news release.

As previously reported, Eisai agreed to acquire MGI Pharma in a transaction valued at about $3.9 billion.

MGI Pharma is a Bloomington, Minn., biopharmaceutical company.

Eisai is a research-based human health care company based in Tokyo.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.